tDCS to Decrease Opioid Relapse (UG3)

NACompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

April 30, 2023

Study Completion Date

August 31, 2023

Conditions
Opioid DependenceCraving
Interventions
DEVICE

tDCS

Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.

DEVICE

sham tDCS

Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.

Trial Locations (1)

02906

Butler Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Butler Hospital

OTHER